Fake Mounjaro Wax-Seal: ₹70 Lakh Worth of Counterfeit Tirzepatide Injections Seized in Gurugram Sting

GURUGRAM — In a major crackdown on India’s booming metabolic health market, Haryana drug regulators and local police intercepted a massive consignment of counterfeit Mounjaro (tirzepatide) injections worth approximately ₹70 lakh in Gurugram’s DLF Phase-IV. The sting operation, which resulted in the arrest of two individuals, has exposed a sophisticated illegal manufacturing ring and reignited urgent warnings regarding the safety of GLP-1 therapies obtained outside formal medical channels.

The seizure comes as demand for tirzepatide—a dual-action medication approved for type 2 diabetes and obesity—skyrockets across India. Since its launch in early 2025, Mounjaro has become one of the country’s top-selling pharmaceuticals, creating a supply-demand vacuum that illicit “basement” manufacturers are now moving to exploit.

The Sting: How the Racket Operated

The operation was triggered by a tip-off leading authorities to a private vehicle near Super Mart-1. Inside, officials from the Haryana Food and Drug Control Administration (FDA) discovered multiple cartons of “Mounjaro KwikPens” across various dosages ($2.5\text{ mg}$ to $15\text{ mg}$).

Investigation reveals a troubling “DIY” approach to pharmaceutical manufacturing. The primary accused, a professional with a background in the pharmaceutical sector, allegedly sourced active-substance powders from Chinese e-commerce platforms like Alibaba. These raw materials were then manually assembled into pens at a private property without any drug-licensing authorization.

To entice buyers, the counterfeiters listed the products on B2B platforms like IndiaMART at nearly 27% below the market price of genuine Eli Lilly products, which typically range from ₹3,500 to ₹6,875 per pen.

Spotting the Fakes: Red Flags for Consumers

Regulators have flagged several glaring discrepancies that differentiate these seized goods from authentic Eli Lilly-manufactured Mounjaro:

• Labeling and Packaging: Mismatched font sizes, altered punctuation, and inconsistent formats for manufacturing details.

• Cold-Chain Lapses: While the pens were found in ice boxes, they were not maintained within the strictly required $2^\circ\text{C}$ to $8^\circ\text{C}$ range.

• Missing Documentation: The suspects could not produce valid licenses for storage, distribution, or sale.

“These products are suspicious and counterfeit items,” a spokesperson for Eli Lilly and Company (India) confirmed in a statement. “Such illicit products can pose serious safety risks to patients, and we are cooperating fully with law enforcement to protect the public.”

The High Stakes of “Metabolic” Weight Loss

The surge in demand for GLP-1 drugs (Glucagon-like peptide-1 receptor agonists) is driven by their high efficacy in weight management. In India, where diabetes prevalence is rising alongside obesity, Mounjaro reported sales of roughly ₹114 crore in a single month following its 2025 KwikPen launch.

However, medical experts warn that the “social media hype” surrounding these drugs often obscures their clinical complexity.

“Patients frequently come to clinics asking for Mounjaro by name after seeing influencers promote it,” says a Delhi-based endocrinologist who requested anonymity. “What is often lost in the digital noise is that these are potent biologic drugs. When you bypass a physician and a licensed pharmacist, you aren’t just saving money—you are gambling with your life.”

Comparison of Genuine vs. Counterfeit Risks

Serious Health Risks: Beyond the Surface

Health authorities and independent medical professionals warn that using counterfeit injectables carries three primary categories of risk:

1. Chemical Contamination: Eli Lilly has previously detected sugar alcohols and entirely different chemical compounds in counterfeit batches. These can cause unpredictable allergic reactions or systemic toxicity.

2. Infection Risk: Non-sterile assembly can introduce bacteria into the pen. “Injecting a contaminated substance can lead to localized abscesses, sepsis-like reactions, or blood-borne infections,” warned a senior endocrinologist from a leading national institute.

3. Acute Complications: Inaccurate dosing of tirzepatide can trigger severe gastrointestinal distress, including intractable vomiting or even life-threatening pancreatitis.

Regulatory and Legal Fallout

The two suspects have been booked under the Drugs and Cosmetics Act, 1940, specifically targeting the sale of “spurious drugs” (Section 17B). Samples have been dispatched to state-level labs to determine the exact chemical composition of the seized liquids.

This bust reflects a global trend. Eli Lilly has recently filed multiple lawsuits in the United States against compounding pharmacies and “med-spas” for selling unapproved tirzepatide products, emphasizing that the global shortage of these drugs has created a “perfect storm” for counterfeiters.

Expert Advice for Patients

To ensure safety, patients and health-conscious consumers should adhere to the following guidelines:

• Verified Sources Only: Only purchase GLP-1 medications from licensed hospital pharmacies or reputable retail chains that provide a tax invoice and batch details.

• Scrutinize the Packaging: Look for the manufacturer’s toll-free number and clear, professional printing. If the price seems “too good to be true,” it almost certainly is.

• Medical Supervision: Tirzepatide is not a cosmetic accessory. It requires a prescription and monitoring by an endocrinologist or internal medicine specialist to manage potential side effects on the thyroid and gallbladder.

• Report Suspicion: If you encounter a suspicious pen or an unauthorized seller, contact the National Consumer Helpline or the State Drug Controller.

While the Gurugram seizure is a victory for law enforcement, the scale of the operation suggests that more counterfeit products may already be in circulation. Consumers are urged to remain vigilant and prioritize safety over convenience.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

1. Hindustan Times. “Fake Mounjaro injections worth ₹56 lakh seized in Gurugram; 2 held.” April 19, 2026.

2. India Today. “Raw materials from Alibaba used in fake Mounjaro drug racket busted in Haryana.” April 19, 2026.

3. The Hindu BusinessLine. “Haryana drugs regulator reports fake Mounjaro seizure in Gurugram: Eli Lilly.” April 20, 2026.

4. Moneycontrol. “Haryana drug regulator busts fake Mounjaro racket, seizes Rs 70-lakh stock in Gurugram.” April 19-20, 2026.